BiotechTube
Strike Pharma

Strike Pharma

Stockholm, Sweden· Est.
strikepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Strike Pharma is an early-stage biotechnology company pioneering a novel approach to in vivo CAR-T therapy through targeted LNP delivery. Its core technology is based on a high-affinity, picomolar interaction between a proprietary synthetic peptide tag (pTag) and an scFv antibody fragment, allowing for the post-storage conjugation of targeting antibodies to LNPs. This platform aims to overcome key challenges in CAR-T manufacturing, storage, and administration, offering a potential off-the-shelf, non-viral alternative to current ex vivo CAR-T and in vivo viral vector approaches. The company's lead concept candidate, STR3/19, targets B-cell driven autoimmune diseases.

Autoimmune DiseaseOncology

Technology Platform

Proprietary affinity conjugation technology using a synthetic peptide tag (pTag) and scFv antibody fragment for post-storage attachment of targeting bispecific antibodies to lipid nanoparticles (LNPs), enabling targeted in vivo delivery of mRNA payloads for cell reprogramming.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The platform could enable off-the-shelf, repeatable in vivo CAR-T therapies, dramatically expanding access beyond current expensive and complex ex vivo methods.
The focus on autoimmune diseases taps into a nascent multi-billion dollar market with high unmet need, where a transient, non-viral approach may have significant safety and practicality advantages over permanent viral-based therapies.

Risk Factors

The technology is at a preclinical stage with unproven efficacy and safety in humans.
The company faces intense competition in the in vivo cell therapy space from better-funded entities using both viral and non-viral approaches.
As a small, private, pre-revenue company, it carries significant funding and execution risk.

Competitive Landscape

Strike Pharma competes in the rapidly evolving field of in vivo generated cell therapies. Key competitors include companies developing viral vector-based in vivo CAR-T (e.g., Capstan Therapeutics, Umoja Biopharma) and other non-viral/LNP targeting platforms (e.g., ReCode Therapeutics, Beam Therapeutics in broader LNP delivery). Its differentiation lies in its post-storage conjugation system aimed at solving LNP stability issues and its specific focus on autoimmune disease as a first indication.

More companies in Sweden →